Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma
- Ioana Agache
- , Jessica Beltran
- , Cezmi Akdis
- , Mubeccel Akdis
- , Carlos Canelo-Aybar
- , Giorgio Walter Canonica
- , Thomas Casale
- , Tomas Chivato
- , Jonathan Corren
- , Stefano Del Giacco
- , Thomas Eiwegger
- , Davide Firinu
- , James E. Gern
- , Eckard Hamelmann
- , Nicola Hanania
- , Mika Mäkelä
- , Irene Hernández-Martín
- , Parameswaran Nair
- , Liam O'Mahony
- , Nikolaos G. Papadopoulos
- Transilvania University of Brasov
- Research Institute of the Santa Creu i Sant Pau Hospital
- University of Zurich
- Christine Kühne – Center for Allergy Research and Education
- Biomedical Research Networking Center in Epidemiology and Public Health (CiberESP)
- IRCCS Istituto Clinico Humanitas - Rozzano (Milano)
- University of South Florida
- CEU Universities
- University of California at Los Angeles
- University of Cagliari
- University of Toronto
- University of Wisconsin-Madison
- Klinik für Kinder- und Jugendmedizin Kinderzentrum Bethel
- Baylor College of Medicine
- Hospital District of Helsinki and Uusimaa
- Hospital Universitario La Paz
- McMaster University
- University of Manchester
- National and Kapodistrian University of Athens
- University of Ferrara
- Ajou University
- Hospital Lucus Augusti
- Hospital del Mar
- Universidad Autónoma de Madrid
- Imperial College London
- MRC & Asthma UK Centre in Allergic Mechanisms of Asthma
- University of Edinburgh
- Complutense University
- University of Wrocław
- “ALL-MED” Medical Research Institute
Research output: Contribution to journal › Article › peer-review